People · Operator
Named in public records as an officer, director or promoter · active 2017–2017 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Syntimmune, Inc. | — | Biotechnology | Series B | $26.0M | $714.4M | 2017 |
Sam Hall, Ph.D. at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Sam Hall, Ph.D. on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Seth Harrison | 1 | 19 |
| Geeta Vemuri | 1 | 7 |
| Aaron Kantoff | 1 | 6 |
| Sam Hall | 1 | 3 |
| DAVID DE GRAAF, PH.D. | 1 | 2 |
| Seth Harrison, M.D. | 1 | 1 |
| Richard Blumberg, M.D. | 1 | 1 |
| Burt Adelman, M.D. | 1 | 1 |
| Laurence Blumberg, M.D. | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.